MeerMinder Bedrijfsinformatie

Galapagos NV ABOUT US History Executive Team Board of Directors R&D Pipeline GLPG0634 – RA/Crohn's GLPG1205/GLPG1690 – Inflammatory diseases MOR106 - Inflammatory diseases GLPG0778/555 – immun/inflam GLPG0974 - inflammation Alliances Cancer Inflammatory diseases Inflammation - GSK Osteoarthritis Inflammation - Janssen Cystic fibrosis Business Development Approach Clinical trials FIDELTA INVESTORS Financials Key financials Financial reports Financial Calendar Stock Information Stock charts Share capital Analyst coverage Dividends Corporate Governance Articles of Association Special Reports Statutory Auditor Agreements Charter Shareholder Information Shareholders' Meetings Shareholder Rights Major Shareholders Financial Service FAQs Transparency Notices NEWS & EVENTS Press releases Events & presentations Media inquiries Jefferies Healthcare Conference CF&B Small and Midcap Event GLPG in the news Scientific meetings Archive Posters Presentations Webcast Publications CAREERS Current openings CONTACT Oct 15, 2014 Bart Filius joins Galapagos as CFO   2012 2013 2014 2015 2016 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Galapagos is a clinical stage biotech company focused on developing novel mode of action medicines.  Headquartered in Belgium, the Company employs 400 people and reported 2013 revenues of €160 million.  Charles River acquired the BioFocus and Argenta service operations on 1 April Q2 2014 – click here to read more. Galapagos’ most advanced candidate drug GLPG0634 shows excellent safety and efficacy  in rheumatoid arthritis patients and is fully proprietary to Galapagos. With GLPG0634, Galapagos demonstrates its capabilities in developing novel medicines  for difficult to cure diseases. Click here to access the NACFC 2014 poster on novel correctors Click here to access the R&D update 2014 webcast, or click here to see the presentation Click here to view the GLPG0634 metabolite poster at EULAR 2014 Click here to view the GLPG0634 modeling poster at EULAR 2014 Click here to view the GLPG0634 DDI abstract for EULAR 2014  Click here to acces the DDW presentation for GLPG0634 Click here to access the AACR poster for GLPG1790 Click here to view the GLPG0634 poster at ECCO 2014 Click here to view the NACFC 2013 poster Learn more about GLPG0634’s selective JAK1 profile Interview with Dr. Frédéric Vanhoutte: GLPG0634 Proof of Concept results © Copyright 2014 Galapagos NV | Disclaimer | General Purchase Terms Test